270 related articles for article (PubMed ID: 26349666)
1. PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer.
Cheng S; Zheng J; Zhu J; Xie C; Zhang X; Han X; Song B; Ma Y; Liu J
Int J Biol Markers; 2015 Nov; 30(4):e364-8. PubMed ID: 26349666
[TBL] [Abstract][Full Text] [Related]
2. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
3. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
4. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
Akamine T; Takada K; Toyokawa G; Kinoshita F; Matsubara T; Kozuma Y; Haratake N; Takamori S; Hirai F; Tagawa T; Okamoto T; Yoneshima Y; Okamoto I; Shimokawa M; Oda Y; Nakanishi Y; Maehara Y
Surg Oncol; 2018 Mar; 27(1):88-94. PubMed ID: 29549910
[TBL] [Abstract][Full Text] [Related]
5. Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients.
He J; Pan Y; Guo Y; Li B; Tang Y
J Immunother; 2020 Jun; 43(5):156-164. PubMed ID: 32168233
[TBL] [Abstract][Full Text] [Related]
6. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
[TBL] [Abstract][Full Text] [Related]
7. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
[TBL] [Abstract][Full Text] [Related]
8. Association between single nucleotide polymorphism of PD-L1 gene and non-small cell lung cancer susceptibility in a Chinese population.
Chen YB; Mu CY; Chen C; Huang JA
Asia Pac J Clin Oncol; 2014 Jun; 10(2):e1-6. PubMed ID: 23167931
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples.
Casadevall D; Clavé S; Taus Á; Hardy-Werbin M; Rocha P; Lorenzo M; Menéndez S; Salido M; Albanell J; Pijuan L; Arriola E
Clin Lung Cancer; 2017 Nov; 18(6):682-691.e5. PubMed ID: 28549836
[TBL] [Abstract][Full Text] [Related]
11. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
Zhou C; Che G; Zheng X; Qiu J; Xie Z; Cong Y; Pei X; Zhang H; Sun H; Ma H
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338
[TBL] [Abstract][Full Text] [Related]
12. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
Takeuchi M; Doi T; Obayashi K; Hirai A; Yoneda K; Tanaka F; Iwai Y
Immunol Lett; 2018 Apr; 196():155-160. PubMed ID: 29366663
[TBL] [Abstract][Full Text] [Related]
13. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
14. [The level of soluble programmed death-1 in peripheral blood of patients with lung cancer and its clinical implications].
Xing YF; Zhang ZL; Shi MH; Ma Y; Chen YJ
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):102-6. PubMed ID: 22455965
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 rs2890658 Polymorphism Increases Risk for Non-Small-Cell Lung Cancer in Northern China Population Based on Experimental Data and Meta-Analysis.
Wang G; Dong Y; Yang Y; Zhang W; Liu N; Wei Y
Contrast Media Mol Imaging; 2022; 2022():8433489. PubMed ID: 35992543
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
[TBL] [Abstract][Full Text] [Related]
17. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056
[TBL] [Abstract][Full Text] [Related]
18. Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers.
Pawelczyk K; Piotrowska A; Ciesielska U; Jablonska K; Gletzel-Plucinska N; Grzegrzolka J; Podhorska-Okolow M; Dziegiel P; Nowinska K
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30769852
[TBL] [Abstract][Full Text] [Related]
19. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.
Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Yoshida H; Yagi Y; Sakamori Y; Nagai H; Hirai T; Kim YH
Sci Rep; 2017 Mar; 7():45124. PubMed ID: 28332580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]